Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

RCUS

Arcus Biosciences (RCUS)

Arcus Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:RCUS
DatumZeitQuelleÜberschriftSymbolFirma
08/06/202400h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:RCUSArcus Biosciences Inc
08/06/202400h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:RCUSArcus Biosciences Inc
08/06/202400h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:RCUSArcus Biosciences Inc
06/06/202422h28Edgar (US Regulatory)Form 8-K - Current reportNYSE:RCUSArcus Biosciences Inc
06/06/202422h05Business WireArcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:RCUSArcus Biosciences Inc
03/06/202414h18Edgar (US Regulatory)Form 8-K - Current reportNYSE:RCUSArcus Biosciences Inc
02/06/202414h00Business WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNYSE:RCUSArcus Biosciences Inc
02/06/202414h00Business WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNYSE:RCUSArcus Biosciences Inc
01/06/202414h00Business WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNYSE:RCUSArcus Biosciences Inc
01/06/202414h00Business WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNYSE:RCUSArcus Biosciences Inc
24/05/202422h35Business WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
23/05/202422h59Edgar (US Regulatory)Form 8-K - Current reportNYSE:RCUSArcus Biosciences Inc
09/05/202422h35Business WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
08/05/202422h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:RCUSArcus Biosciences Inc
08/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNYSE:RCUSArcus Biosciences Inc
08/05/202422h02Business WireArcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline UpdateNYSE:RCUSArcus Biosciences Inc
02/05/202422h05Business WireArcus Biosciences to Participate in the Bank of America Healthcare Conference 2024NYSE:RCUSArcus Biosciences Inc
24/04/202422h00Business WireArcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual MeetingNYSE:RCUSArcus Biosciences Inc
23/04/202422h05Business WireArcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline UpdateNYSE:RCUSArcus Biosciences Inc
09/04/202422h35Business WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
26/03/202421h35Business WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
11/03/202421h35Business WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
28/02/202422h05Business WireArcus Biosciences to Participate in Two Upcoming Investor ConferencesNYSE:RCUSArcus Biosciences Inc
27/02/202422h35Business WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
21/02/202422h53Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNYSE:RCUSArcus Biosciences Inc
21/02/202422h32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:RCUSArcus Biosciences Inc
21/02/202422h08Edgar (US Regulatory)Form 8-K - Current reportNYSE:RCUSArcus Biosciences Inc
21/02/202422h05Business WireArcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline UpdateNYSE:RCUSArcus Biosciences Inc
09/02/202422h35Business WireArcus Biosciences Announces New Employment Inducement GrantsNYSE:RCUSArcus Biosciences Inc
08/02/202400h58Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:RCUSArcus Biosciences Inc
 Showing the most relevant articles for your search:NYSE:RCUS

Kürzlich von Ihnen besucht

Delayed Upgrade Clock